Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.

Current opinion in oncology - 1 Mar 2015

Pirker Robert

Abstract excerpt

PURPOSE OF REVIEW: The epidermal growth factor receptor (EGFR) is overexpressed in many nonsmall cell lung cancers (NSCLCs). Blockade of EGFR by monoclonal antibodies has been studied as a strategy to improve the outcome of first-line chemotherapy in patients with NSCLC. The present review updates the findings from phase III trials. RECENT FINDINGS: Cetuximab improved survival when combined with first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Cisplatin

Share to Clinical Trials, Phase III as Topic

Share to Molecular Targeted Therapy

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 25636162
DOI: 10.1097/CCO.0000000000000162

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.PMID 25636162Read ↗

EGFR-directed monoclonal antibodies in non-small cell lung cancer.Semantic proximity Read ↗

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Monoclonal antibodies in lung cancer.Semantic proximity Read ↗

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.Semantic proximity Read ↗

EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.Semantic proximity Read ↗

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.Semantic proximity Read ↗

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Semantic proximity Read ↗

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.Semantic proximity Read ↗

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.